TFF Pharmaceuticals, Inc.
TFFPNASDAQHealthcare
$0.07
$-0.10(-60.05%)
Market Cap$288798
P/E Ratio—
52W High$11.0
52W Low$0.061
TFF Pharmaceuticals, Inc. (TFFP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TFFP · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2024Report Date: Nov 20, 2024EPS Actual
-$0.81
Est. -$0.81 · +0.0%
Revenue
$0.00B
Est. $0.00B · +28.9%
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Nov 20, 2024
After Market Close
▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
TFFP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2024 | Nov 20, 2024 | -$0.81 | -$0.81 | +0.0% | $0.00B | $0.00B | +28.9% |
| ▲ Q3 FY2024 | Aug 14, 2024 | -$1.70 | -$1.22 | +28.2% | $0.00B | $0.00B | +333.5% |
| ▼ Q2 FY2024 | May 14, 2024 | -$2.20 | -$2.40 | -9.1% | $0.00B | $0.00B | +190.4% |
| — Q1 FY2024 | Mar 28, 2024 | -$2.00 | -$2.01 | -0.5% | $0.00B | $0.00B | +633.9% |
| ▲ Q4 FY2023 | Nov 14, 2023 | -$2.75 | -$2.25 | +18.2% | $0.00B | $0.00B | +134.8% |
| ▲ Q3 FY2023 | Aug 15, 2023 | -$5.00 | -$3.50 | +30.0% | $0.00B | $0.00B | +376.2% |
| ▲ Q2 FY2023 | May 11, 2023 | -$5.00 | -$4.75 | +5.0% | $0.00B | $0.00B | -79.4% |
| ▲ Q1 FY2023 | Mar 7, 2023 | -$0.24 | -$0.10 | +58.3% | $0.00B | $0.00B | +900.0% |
Q4 FY2024
Nov 20, 2024
EPS Actual
-$0.81
EPS Est.
-$0.81
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2024
Aug 14, 2024Beat
EPS Actual
-$1.22
EPS Est.
-$1.70
EPS Surpr.
+28.2%
Revenue
$0.00B
Q2 FY2024
May 14, 2024Miss
EPS Actual
-$2.40
EPS Est.
-$2.20
EPS Surpr.
-9.1%
Revenue
$0.00B
Q1 FY2024
Mar 28, 2024
EPS Actual
-$2.01
EPS Est.
-$2.00
EPS Surpr.
-0.5%
Revenue
$0.00B
Q4 FY2023
Nov 14, 2023Beat
EPS Actual
-$2.25
EPS Est.
-$2.75
EPS Surpr.
+18.2%
Revenue
$0.00B
Q3 FY2023
Aug 15, 2023Beat
EPS Actual
-$3.50
EPS Est.
-$5.00
EPS Surpr.
+30.0%
Revenue
$0.00B
Q2 FY2023
May 11, 2023Beat
EPS Actual
-$4.75
EPS Est.
-$5.00
EPS Surpr.
+5.0%
Revenue
$0.00B
Q1 FY2023
Mar 7, 2023Beat
EPS Actual
-$0.10
EPS Est.
-$0.24
EPS Surpr.
+58.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q3 FY2025 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q2 FY2025 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q1 FY2025 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q4 FY2024 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q3 FY2024 | $-0.81 | $-0.81 | $-0.81 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2024 | Nov 20, 2024 | +0.0% | $0.40 | $0.37 | -5.94% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +28.2% | $1.97 | $2.04 | +3.55% |
| ▼ Q2 FY2024 | May 14, 2024 | -9.1% | $1.81 | $1.86 | +2.76% |
| ▲ Q1 FY2024 | Mar 28, 2024 | -0.5% | $6.59 | $6.04 | -8.35% |
| ▲ Q4 FY2023 | Nov 14, 2023 | +18.2% | $5.50 | $5.95 | +8.14% |
| ▲ Q3 FY2023 | Aug 15, 2023 | +30.0% | $11.25 | $10.25 | -8.89% |
| ▲ Q2 FY2023 | May 11, 2023 | +5.0% | $17.00 | $16.75 | -1.47% |
| ▲ Q1 FY2023 | Mar 7, 2023 | +58.3% | $21.61 | $21.64 | +0.13% |
Q4 FY2024-5.94%
Report Date
Nov 20, 2024
EPS Beat/Miss
+0.0%
Price Before
$0.40
Price After
$0.37
Q3 FY2024+3.55%
Report Date
Aug 14, 2024
EPS Beat/Miss
+28.2%
Price Before
$1.97
Price After
$2.04
Q2 FY2024+2.76%
Report Date
May 14, 2024
EPS Beat/Miss
-9.1%
Price Before
$1.81
Price After
$1.86
Q1 FY2024-8.35%
Report Date
Mar 28, 2024
EPS Beat/Miss
-0.5%
Price Before
$6.59
Price After
$6.04
Q4 FY2023+8.14%
Report Date
Nov 14, 2023
EPS Beat/Miss
+18.2%
Price Before
$5.50
Price After
$5.95
Q3 FY2023-8.89%
Report Date
Aug 15, 2023
EPS Beat/Miss
+30.0%
Price Before
$11.25
Price After
$10.25
Q2 FY2023-1.47%
Report Date
May 11, 2023
EPS Beat/Miss
+5.0%
Price Before
$17.00
Price After
$16.75
Q1 FY2023+0.13%
Report Date
Mar 7, 2023
EPS Beat/Miss
+58.3%
Price Before
$21.61
Price After
$21.64
Avg Beat Reaction-1.83%
Avg Miss Reaction+2.76%
Beat Rate7 / 8 quarters
Largest Move-8.89% (Q3 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TFFP ends December
TFF Pharmaceuticals, Inc. (TFFP) most recently reported earnings on November 20, 2024 for Q4 FY2024, posting EPS of $-0.81 (in line with the analyst consensus of $-0.81). TFFP has beaten EPS estimates for 2 consecutive quarters. The next TFFP earnings date is expected around September 1, 2026.
Each quarter, investors track TFFP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TFFP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TFFP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TFFP earnings · 4 questionsTFF Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. TFFP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TFFP historically reports after market close (AMC).
TFFP earnings datewhen is TFFP earningsTFFP next earnings datewhen does TFFP report earningsTFFP earnings calendar
▸ Source: FMP · TFF Pharmaceuticals, Inc. SEC filings · US GAAP · TFF Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026